Lv5
814 积分 2026-10-19 加入
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
21小时前
待审核
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
1天前
已采纳
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
1天前
已采纳
Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
1天前
已采纳
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
1天前
已采纳
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
1天前
已采纳
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
1天前
已采纳
Biomarkers of Pathological Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair Deficiency Colorectal Cancer
1天前
已采纳
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer
1天前
已采纳
Rivaroxaban
Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial
皖公网安备34019202002308
